Patient characteristics by treatment arm and EGFR status determined on tumour tissue (n=250)
| EOX arm | EOX-P arm | |||
| EGFR non-amplified (<2) | EGFR amplified (≥2) | EGFR non-amplified (<2) | EGFR amplified (≥2) | |
| Median age (IQR) | 62.6 (54.2–68.4) | 63.8 (54.3–68.6) | 63.2 (56.6–69.7) | 63.1 (59.0–65.4) |
| Males (%) | 97 (80.8) | 7 (100) | 89 (78.8) | 10 (100) |
| Females (%) | 23 (19.2) | – | 24 (21.2) | – |
| PS 0 (%) | 44 (36.7) | 4 (57.1) | 42 (37.2) | 5 (50) |
| PS 1 (%) | 69 (57.5) | 2 (28.6) | 65 (57.5) | 5 (50) |
| PS 2 (%) | 7 (5.8) | 1 (14.3) | 6 (5.3) | – |
| Locally advanced (%) | 8 (6.7) | – | 10 (8.9) | 1 (10) |
| Metastatic (%) | 112 (93.3) | 7 (100) | 103 (91.1) | 9 (90) |
EGFR, epidermal growth factor receptor; EOX, epirubicin, oxaliplatin, capecitabine; P, panitumumab; PS, performance status.